If the anti-IFN autoantibodies do contribute to the candidiasis, then cautious treatment with IFN-γ might be considered for intractable cases (with no anti-IFN-γ antibodies); use of IFN-β might carry some risk of autoimmune complications [40]. The gene discussed is IFNG; the disease is candidiasis.